Cancer Vaccines from Research to Clinical Practice
Total Page：16
File Type：pdf, Size：1020Kb
Cancer Vaccines From Research to Clinical Practice Cancer Vaccines From Research to Clinical Practice Edited by Adrian Bot, MD, PhD Chief Scientifi c Offi cer, Kite Pharma, Inc., Los Angeles, California, USA Mihail Obrocea, MD Head, Clinical Development–Oncology, Abbott Biotherapeutics Corporation, Redwood City, California, USA and Francesco Marincola, MD Chief, Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center; Associate Director, Trans-NIH Center for Human Immunology, National Institutes of Health; Director, CC/CHI FOCIS Center of Excellence; President Elect, Society for the Immunotherapy of Cancer; President Elect, International Society for Translational Medicine, Bethesda, Maryland, USA Published in 2011 by Informa Healthcare, Telephone House, 69-77 Paul Street, London EC2A 4LQ, UK. Simultaneously published in the USA by Informa Healthcare, 52 Vanderbilt Avenue, 7th Floor, New York, NY 10017, USA. Informa Healthcare is a trading division of Informa UK Ltd. Registered Offi ce: 37–41 Mortimer Street, London W1T 3JH, UK. Registered in England and Wales number 1072954. © 2011 Informa Healthcare, except as otherwise indicated No claim to original U.S. Government works Reprinted material is quoted with permission. Although every effort has been made to ensure that all owners of copyright material have been acknowledged in this publication, we would be glad to acknowledge in subsequent reprints or editions any omissions brought to our attention. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, unless with the prior written permission of the publisher or in accordance with the provisions of the Copyright, Designs and Patents Act 1988 or under the terms of any licence permitting limited copying issued by the Copyright Licensing Agency Saffron House, 6-10 Kirby Street, London EC1N 8TS UK, or the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA (http://www. copyright. com/ or telephone 978-750-8400). Product or corporate names may be trademarks or registered trademarks, and are used only for identifi cation and explanation without intent to infringe. This book contains information from reputable sources and although reasonable efforts have been made to publish accurate information, the publisher makes no warranties (either express or implied) as to the accuracy or fi tness for a particular purpose of the information or advice contained herein. The publisher wishes to make it clear that any views or opinions expressed in this book by individual authors or contributors are their personal views and opinions and do not necessarily refl ect the views/opinions of the publisher. Any information or guidance contained in this book is intended for use solely by medical professionals strictly as a supplement to the medical professional’s own judgement, knowledge of the patient’s medical history, relevant manufacturer’s instructions and the appropriate best practice guidelines. Because of the rapid advances in medical science, any information or advice on dosages, procedures, or diagnoses should be independently verifi ed. This book does not indicate whether a particular treatment is appropriate or suitable for a particular individual. Ultimately it is the sole responsibility of the medical professional to make his or her own professional judgements, so as appropriately to advise and treat patients. Save for death or personal injury caused by the publisher’s negligence and to the fullest extent otherwise permitted by law, neither the publisher nor any person engaged or employed by the publisher shall be responsible or liable for any loss, injury or damage caused to any person or property arising in any way from the use of this book. A CIP record for this book is available from the British Library. ISBN-13: 978-1-84184-829-7 Orders may be sent to: Informa Healthcare, Sheepen Place, Colchester, Essex CO3 3LP, UK Telephone: +44 (0)20 7017 6682 Email: [email protected] Website: http://informahealthcarebooks.com Library of Congress Cataloging-in-Publication Data Cancer vaccines : from research to clinical practice / edited by Adrian Bot, Mihail Obrocea, Francesco Marincola. p. ; cm. Includes bibliographical references and index. ISBN 978-1-84184-829-7 (hardback : alk. paper) 1. Cancer vaccines. I. Bot, Adrian. II. Obrocea, Mihail. III. Marincola, Francesco M. [DNLM: 1. Cancer Vaccines--therapeutic use. QZ 266] RC271.I45C42 2011 616.99’4061--dc23 2011017121 For corporate sales please contact: [email protected] For foreign rights please contact: [email protected] For reprint permissions please contact: [email protected] Typeset by Exeter Premedia Services Private Ltd., Chennai, India Printed and bound in the United Kingdom. The editors dedicate this book to all translational researchers, drug developers, clinicians, and entrepreneurs, who never gave up on the concept of active immunotherapy for cancer as a viable and promising option for oncology patients, for the present and future. Contents Contributors ix Foreword xiv Preface xv 1. Introduction: Cancer vaccines—mechanism and a clinical overview 1 Antoni Ribas and Adrian Bot 2. Revisiting the paradigm on the putative need for antigen-specifi c responses in cancer 9 Gail D. Sckisel , Julia K. Tietze, and William J. Murphy VACCINE PLATFORMS FOR GENITO-URINARY CANCERS, WITH POTENTIAL APPLICABILITY TO OTHER TUMORS 3. Development of novel immune interventions for genito-urinary cancers 25 Neeraj Agarwal and Nicholas J. Vogelzang 4. Autologous cellular immunotherapy in late-stage prostate cancer: The development history of Sipuleucel-T (PROVENGE®) 44 David L. Urdal and Mark W. Frohlich 5. Design, development, and translation of poxvirus-based vaccines for cancer 56 Benedetto Farsaci, Anna Kwilas, and James W. Hodge VACCINES FOR SOLID CANCERS AND HEMATOLOGICAL MALIGNANCIES 6. Of mice and men (and dogs!): The fi rst approved cancer therapy vaccine 78 Philip J. Bergman and Jedd D. Wolchok 7. Recombinant protein vaccination for antigen-specifi c cancer immunotherapy 87 Pedro de Sousa Alves and Vincent Brichard 8. Antigen-targeted synthetic vaccines for metastatic cancer 103 Zhiyong Qiu, David C. Diamond, Kent A. Smith, Dar Rosario, Sabrina Miles, Mihail Obrocea, Thomas M. Kundig, and Adrian Bot 9. Clinical perspectives in cancer vaccines for hematological diseases 126 Maurizio Chiriva-Internati, Leonardo Mirandola, Marjorie Jenkins, Martin Cannon, Everardo Cobos, and W. Martin Kast 10. Epitope-based vaccines for cancer 140 Vy Phan-Lai, Denise L. Cecil, Gregory E. Holt, Daniel R. Herendeen, Forrest Kievit, Miqin Zhang, and Mary L. Disis VACCINE DEVELOPMENT: TRIAL DESIGN AND IMMUNE ASSAYS 11. Emerging clinical trial design concepts for therapeutic cancer vaccines 150 Cristina Musselli, Leah Isakov, and Kerry Wentworth CONTENTS 12. T-cell immune monitoring assays to guide the development of new cancer vaccines 156 Cedrik M. Britten, Sylvia Janetzki, Cécile Gouttefangeas, Marij J. P. Welters, Michael Kalos, Christian Ottensmeier, Axel Hoos, and Sjoerd H. van der Burg 13. A biomarker-based, systems biology approach guiding the development of active immunotherapies and immune monitoring 167 Glenda Canderan, Peter Wilkinson, John Schatzle, Mark Cameron, and Rafi ck-Pierre Sekaly EMERGING NEW VACCINE STRATEGIES, TARGETS, AND ADJUVANTS 14. Targeting regulatory T cells and other strategies to enable cancer vaccines 182 Christopher Paustian, Shawn M. Jensen, Sarah Church, Sachin Puri, Chris Twitty, Hong-Ming Hu, Brendan D. Curti, Walter J. Urba, Raj K. Puri, and Bernard A. Fox 15. Molecular targeting of cancer stem cells 202 Zhenhua Li, Debraj Mukherjee, Jang-Won Lee, and John S. Yu 16. RNA in cancer vaccine therapy 217 Smita Nair, David Boczkowski, Scott Pruitt, and Johannes Urban 17. Induction of innate immunity by nucleic acids: A potential adjuvant for cancer vaccines? 232 Bo Jin and Anthony E. T. Yeo NEXT-GENERATION HYBRID ACTIVE/PASSIVE IMMUNOTHERAPIES 18. Passive immunotherapy by T cell–engaging bispecifi c antibodies 250 Patrick A. Baeuerle and Benno Rattel 19. Antibodies to peptide–HLA complexes have potential application for cancer diagnosis and therapy 263 Jon A. Weidanz and William H. Hildebrand Index 277 viii Contributors Neeraj Agarwal Assistant Professor of Medicine, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, USA Patrick A. Baeuerle Senior Vice President, Chief Scientifi c Offi cer, Micromet AG, Munich, Germany Philip J. Bergman Chief Medical Offi cer, BrightHeart Veterinary Centers, Armonk, NY, USA; Adjunct Associate, Memorial Sloan-Kettering Cancer Center, New York, NY, USA David Boczkowski Department of Surgery, Duke University Medical Center, Durham, NC, USA Adrian Bot Chief Scientifi c Offi cer, Kite Pharma, Inc., Los Angeles, CA, USA Vincent Brichard Vice President, Cancer Immunotherapeutics, GlaxoSmithKline Biologicals, Rixensart, Belgium Cedrik M. Britten Johannes Gutenberg–University Mainz, Department of Internal Medicine III, Division of Experimental Oncology, and Ribological GmbH, Mainz, Germany Mark Cameron Vaccine and Gene Therapy Institute, Port Saint Lucie, FL, USA Glenda Canderan Vaccine and Gene Therapy Institute, Port Saint Lucie, FL, USA Martin Cannon Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, AR, USA Denise L. Cecil Senior Fellow, Department of Medicine, University